Cargando…

Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China

The study aims to examine the treatment effect and adverse reactions of patients with newly diagnosed MM receiving different bortezomib-based regimens. This was a retrospective study of patients with newly diagnosed MM and who were treated with bortezomib-based combined chemotherapy at the Departmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Rongxin, Hu, Xudong, Zhou, Shuping, Zhang, Qianying, Huang, He, Sun, Ni, Guo, Wenjian, Yu, Kang, Lin, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	4800
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775427/ https://www.ncbi.nlm.nih.gov/pubmed/31574817 http://dx.doi.org/10.1097/MD.0000000000017147

Ejemplares similares

Combined immune score predicts the prognosis of newly diagnosed multiple myeloma patients in the bortezomib-based therapy era
por: Wei, Min, et al.
Publicado: (2021)

Bortezomib-based regimens improve the prognosis of newly diagnosed MM patients with chromosomal aberrations except for del(17q13): A retrospective study from a single center
por: Liu, Zhigang, et al.
Publicado: (2021)

Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia
por: Yao, Mingkang, et al.
Publicado: (2022)

Bortezomib-based treatment for multiple myeloma patients with renal impairment: A systematic review and meta-analysis of observational studies
por: Zhu, Wanqiu, et al.
Publicado: (2016)

A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma
por: Wei, Daolin, et al.
Publicado: (2016)

Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report
por: Zuo, Wenli, et al.
Publicado: (2017)

Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis
por: Sidana, Surbhi, et al.
Publicado: (2017)

Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
por: Dolph, Michael, et al.
Publicado: (2021)

Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians
por: Banerjee, Rahul, et al.
Publicado: (2023)

Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma
por: Ashrafi, Farzaneh, et al.
Publicado: (2020)

Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial
por: Macdougall, Iain C
Publicado: (2007)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study
por: Sugimoto, T., et al.
Publicado: (2019)

Efficacy of once-weekly and twice-weekly injections of teriparatide by patient characteristics: A post hoc analysis of the TWICE study
por: Sugimoto, Toshitsugu, et al.
Publicado: (2021)

Incremental and Once- to Twice-Weekly Hemodialysis: From Experience to Evidence
por: Obi, Yoshitsugu, et al.
Publicado: (2017)

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
por: Bringhen, Sara, et al.
Publicado: (2019)

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
por: Qian, Wensi, et al.
Publicado: (2020)

Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma
por: Mangiacavalli, Silvia, et al.
Publicado: (2013)

Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article
por: Gao, Yayue, et al.
Publicado: (2017)

Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma
por: Hsu, Pei, et al.
Publicado: (2015)

Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
por: Chiquette, Elaine, et al.
Publicado: (2012)

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
por: Shaw, Jonathan E., et al.
Publicado: (2017)

Whole exome sequencing for diagnosis of hereditary thrombocytopenia
por: Mekchay, Ponthip, et al.
Publicado: (2020)

Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
por: Ciftciler, Rafiye, et al.
Publicado: (2020)

Long-term complications of splenectomy in adult immune thrombocytopenia
por: Thai, Lan-Huong, et al.
Publicado: (2016)

Bortezomib-Based Regimens and Plasma Cell Leukemia
por: Bolaman, Ali Zahit
Publicado: (2021)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients
por: Zhou, Qiaolin, et al.
Publicado: (2022)

Bortezomib
por: Rajappa, Senthil
Publicado: (2010)

Parvovirus B19 infection presenting with neutropenia and thrombocytopenia: Three case reports
por: Shin, Hyoshim, et al.
Publicado: (2019)

Contribution of interleukin 27 serum level to pathogenesis and prognosis in children with immune thrombocytopenia
por: Hassan, Tamer, et al.
Publicado: (2022)

Efficacy and quality of life of Romiplostim in adults and children with immune thrombocytopenia: A review
por: He, Xin, et al.
Publicado: (2022)

Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2018)

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
por: Liu, Jianhao, et al.
Publicado: (2021)

Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma
por: Kim, Kihyun, et al.
Publicado: (2013)

A gene missense mutation in diffuse pulmonary lymphangiomatosis with thrombocytopenia: A case report
por: Zheng, Guixian, et al.
Publicado: (2020)

Immune thrombocytopenia associated with Hashimoto thyroiditis in a pediatric patient: A case report
por: Tian, Zhiqing, et al.
Publicado: (2021)

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023)

Immature platelet fraction: A useful marker for identifying the cause of thrombocytopenia and predicting platelet recovery
por: Jeon, Kibum, et al.
Publicado: (2020)

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
por: He, Jingsong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_prvj3astiql4qdsea2ksu0i7et